Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Blood Advances|December 14, 2019
von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWDFerdows Atiq, Lisette M Schütte, Agnes E M Looijen, et al.
Molecular Cell|January 15, 2000
Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contactsA Georgakopoulos, P Marambaud, S Efthimiopoulos, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 6, 2019
Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above targetLisette M Schütte, Nils de Rooij, Hendrika C A M Hazendonk, et al.
Zentralblatt Fur Gynakologie|December 26, 2001
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]G von Minckwitz, G Raab, M Schütte, et al.
BMJ Open|April 25, 2019
Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID studyLisette M Schütte, Marjon H Cnossen, Reinier M van Hest, et al.
Research and Practice in Thrombosis and Haemostasis|April 25, 2024
Tachyphylaxis and reproducibility of desmopressin response in perioperative persons with nonsevere hemophilia A: implications for clinical practiceL G R Romano, L M Schütte, R M van Hest, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 12, 2024
Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patientsLorenzo G R Romano, Lisette M Schütte, Reinier M van Hest, et al.
JHEP Reports : Innovation in Hepatology|April 30, 2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCCNajib Ben Khaled, Raphael Mohr, Leonie S Jochheim, et al.
Pageof 6